ACR Convergence
About the Event
Date:October 24–29, 2025
Location:Chicago, IL
Credit:CME: TBA, ABIM & ABP MOC: TBA
On Demand:To Be Announced
ACR Convergence is an in-person event, showcasing cutting-edge and timely topics in rheumatology, as well as the prevention, diagnosis, and treatment of rheumatic diseases and related comorbid conditions. ACR Convergence offers hundreds of sessions to educate professionals in every segment of rheumatology. Clinicians, researchers, academicians, practice managers, pediatric rheumatologists, fellows in training, advance practice nurses, physician assistants, physical or occupational therapists: Whatever your role, ACR Convergence is the place to expand your knowledge and skills and pique your curiosity.
Target Audience
Rheumatologists, physicians, and healthcare providers who care for patients with rheumatic diseases, and those interested in or engaged in rheumatology research.
Global Learning Objectives
Upon completion of this activity, participants should be able to:
- Assess their knowledge and competence in various rheumatic diseases and conditions.
- Support their skills in evaluating and diagnosing patients with rheumatic diseases.
- Discuss and collaborate on challenging cases with peers.
- Analyze emerging trends and technologies in rheumatology.
- Employ evidence-based approaches for managing rheumatic conditions.
- Identify new approaches and strategies for patient management.
- Interpret recent clinical trial and research findings.
- Apply new information from basic and clinical science to improve the care of people with rheumatologic illness.
Program Schedule & Syllabi
To Be Announced
Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.
Registration Fees
To Be Announced
On-Demand Access
Registration for ACR Convergence 2024 includes on-demand access to scientific session recordings through October 10, 2025. On-demand recordings do not allow for live participation.
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
For information about the previous meeting, see the ACR Convergence 2024 section below.
ACR Convergence 2025 CME and MOC information to be announced.
The following is the total credit available for ACR Convergence 2024:
CME: 209.50
ABIM & ABP MOC: 209.50
The deadline to claim CME credit and MOC points for ACR Convergence 2024 is November 13, 2025, at 11:59 PM ET.
See full accreditation details, disclosures, and credit claiming instructions.
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
View ACR's ACCME disclosure practices
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
ACR Convergence 2025 Financial Relationships Disclosures to be announced.
See ACR Convergence 2024 Financial Relationships Disclosures in the ACR Convergence 2024 section below.
ACR Convergence 2024 took place November 14–19 at the Walter E. Washington Convention Center in Washington, D.C. We hope you enjoyed unparalleled learning opportunities, allowing you to stay updated on the latest research, advancements, and breakthroughs in the field.
Target Audience
Rheumatologists, physicians, and healthcare providers who care for patients with rheumatic diseases, and those interested in or engaged in rheumatology research.
Global Learning Objectives
Upon completion of this activity, participants should be able to:
- Assess their knowledge and competence in various rheumatic diseases and conditions.
- Support their skills in evaluating and diagnosing patients with rheumatic diseases.
- Discuss and collaborate on challenging cases with peers.
- Analyze emerging trends and technologies in rheumatology.
- Employ evidence-based approaches for managing rheumatic conditions.
- Identify new approaches and strategies for patient management.
- Interpret recent clinical trial and research findings.
- Apply new information from basic and clinical science to improve the care of people with rheumatologic illness.
Program Schedule & Syllabi
ACR Convergence 2024 On-Demand Website
Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.
On-Demand Access
Registration for ACR Convergence 2024 includes on-demand access to scientific session recordings through October 10, 2025. On-demand recordings do not allow for live participation.
CE & MOC Information
The following is the total credit available for ACR Convergence 2024:
CME: 209.50
ABIM & ABP MOC: 209.50
The deadline to claim CME credit and MOC points for ACR Convergence 2024 is November 13, 2025, at 11:59 PM ET.
See full accreditation details, disclosures, and credit claiming instructions.
Financial Relationships Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
Planning Committee Disclosures
Global Financial Relationships Disclosures
Acknowledgement of Commercial Support
Unrestricted medical educational grant support for this activity has been provided by:
Diversity, Equity, and Inclusion
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lilly USA, LLC
Lupus
Aurinia Pharmaceuticals Inc.
Genentech, Inc.
UCB, Inc.